These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1589619)

  • 1. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
    Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 3. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
    Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F
    Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
    Torre GC; Barbetti V; Lanfranco E; Robutti M; Foglia M; Corongiu F; Vigliercio GP
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of CA15-3 in human breast cancer].
    Nihei M; Nomizu T; Tsuchiya A; Abe R
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):987-95. PubMed ID: 3480326
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
    Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
    [No Abstract]   [Full Text] [Related]  

  • 9. [Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast].
    Bumma C; Bramardi AM; Lauria G; Arese P; Marchetti G
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):29-32. PubMed ID: 2092137
    [No Abstract]   [Full Text] [Related]  

  • 10. CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
    Priolo G; Pecchio F; Rapellino M; Aimo G; Spertino F; Pepe C
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):21-3. PubMed ID: 2092121
    [No Abstract]   [Full Text] [Related]  

  • 11. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
    Jäger W
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
    Quaranta M; Micelli G; Coviello M; Donadeo A; Lozupone A; Schittulli F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):35-8. PubMed ID: 2092146
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
    Reale G; Giovagnoli MR; Vecchione A; Cosentino L; Benci F; Manna A; Marchei G; Vittori I; Frati L
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
    [No Abstract]   [Full Text] [Related]  

  • 16. [Serum BCM in patients with nontumorous diseases. Preliminary results].
    Allende MT; Vizoso F; Sampedro A; Ruibal A
    Rev Clin Esp; 1990 Oct; 187(5):254-5. PubMed ID: 2102542
    [No Abstract]   [Full Text] [Related]  

  • 17. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma].
    Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C
    Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
    Silver HK; Archibald BL; Ragaz J; Coldman AJ
    Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M; Wierrani F; Kubista E; Spona J
    Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.